Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV)

NCT00596752 is registered in ClinicalTrials.gov with UCB BIOSCIENCES GmbH as lead sponsor.

NCT NCT00596752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00596752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV)
Lead sponsor
UCB BIOSCIENCES GmbH
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2004
Completion date
July 31, 2013
Enrollment
840 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral arterial occlusive disease